Capecitabine Tablet, Film Coated
Product Images NDC 68001-643

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Capecitabine (NDC 68001-643). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label- Capecitabine Tablets Usp 150 mg (Capecitabine150mglabel)

Label- Capecitabine Tablets Usp 150 mg (Capecitabine150mglabel)
This text provides information about capecitabine tablets containing 150mg of the active ingredient. It includes details on dosage, administration instructions, storage conditions, and manufacturer information. The tablets should be taken whole with water within 30 minutes of a meal and should not be crushed or cut. The medication is classified as a cytotoxic agent and should be stored at 20-25°C. Contact information for the US distributor is also provided along with manufacturing details.*
FDA Label Image

Label- Capecitabine Tablets Usp 500 mg (Capecitabine500mglabel)

Label- Capecitabine Tablets Usp 500 mg (Capecitabine500mglabel)
This text is a description of capecitabine tablets containing 500 mg of capecitabine USP. The tablets are film-coated and should be swallowed whole with water within 30 minutes of a meal. It is emphasized not to crush or cut the tablets and to store them in tight containers at a temperature between 20°C to 25°C (68°F to 77°F). Capecitabine is noted as a cytotoxic agent and a hazardous drug. The manufacturer is Hetero Labs Limited in India, and the contact number for the U.S. is provided as 1-866-495-1995. The prescription is only available with an NDC code of 68001-644-07. Additional details mention instructions for patients, the dispensing of tablets, and the recommended dosage as per prescribing information.*
FDA Label Image

Capecitabinechemicalstructure (Capecitabinechemicalstructure)

FDA Label Image

Capecitabinefigure1 (Capecitabinefigure1)

FDA Label Image

Capecitabinefigure2 (Capecitabinefigure2)

FDA Label Image

Capecitabinefigure3 (Capecitabinefigure3)

Capecitabinefigure3 (Capecitabinefigure3)
This text mentions estimated probabilities, a range from 1.0 to 0.0, and a treatment regimen using 5-FU and Leucovorin known as the Mayo Regimen with Capecitabine dosage specified at 1250 mg/sqm twice daily intermittently.*
FDA Label Image

Capecitabinefigure4 (Capecitabinefigure4)

Capecitabinefigure4 (Capecitabinefigure4)
This is a chart showing estimated probabilities for different doses of Docetaxel and Capecitabine over time in days. It illustrates how the probability changes with different dosage levels.*
FDA Label Image

Capecitabinefigure5 (Capecitabinefigure5)

Capecitabinefigure5 (Capecitabinefigure5)
This is a table showing estimated probabilities for different time scenarios in a medical context. It includes dosages for Docetaxel and Capecitabine for the treatment cycle.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.